Jazz Pharmaceuticals plc is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. Living our core values of integrity, passion, collaboration, innovation and the pursuit of excellence is the key to our success.

JZP-110 PHASE 3 CLINICAL PROGRAM STARTS

JZP-110 is an investigational wake-promoting agent being developed as a treatment for EDS in adult patients with narcolepsy or with OSA. Jazz has worldwide rights to JZP-110, excluding certain jurisdictions in Asia where SK Biopharmaceuticals Co., Ltd retains rights.

Read more


JAZZ IN THE NEWS

CEO Bruce Cozadd interview with Life Sciences Leader: “From Foundation, To Darkest Days, To Finest Hour — The Jazz Pharmaceuticals Success Story.”

Read more

EXPANDED ACCESS PROGRAM

Jazz Pharmaceuticals continues to accrue patients in the defibrotide treatment investigational new drug (T-IND) study in patients diagnosed with hepatic VOD.

Read more

VOD DISEASE AWARENESS

Jazz Pharmaceuticals launches educational campaign to raise awareness of hepatic veno-occlusive disease (VOD).

Read more